WallStSmart

Impact BioMedical, Inc. (IBO)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1894972% more annual revenue ($606.42M vs $32,000). IBO leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

IBO

Avoid

15

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -3.39

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IBO1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.9410/10

Conservative balance sheet, low leverage

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

IBO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$84.10M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : IBO

The strongest argument for IBO centers on Debt/Equity.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : IBO

The primary concerns for IBO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

IBO profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM is growing revenue faster at 1.5% — sustainability is the question.

IBO generates stronger free cash flow (99,000), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 15/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Impact BioMedical, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Leveraging advanced research and development techniques, the firm seeks to improve health outcomes and enhance the overall quality of life for patients. With a robust intellectual property portfolio and a commitment to scientific rigor, Impact BioMedical is well-positioned for substantial growth in the evolving healthcare market. Its expanding product pipeline and strategic collaborations offer attractive opportunities for institutional investors looking to capitalize on transformative developments within the biopharmaceutical sector.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?